Cited by 35Thyroid Disorders and TreatmentsThyroid and Parathyroid SurgeryHelicobacter pylori-related gastroenterology studies

Tablet and oral liquid L-thyroxine formulation in the treatment of naive hypothyroid patients with Helicobacter pylori infection

Ribichini, Danilo, Fiorini, Giulia, Repaci, Andrea, Castelli, Valentina, Gatta, Luigi, Vaira, Dino, Pasquali, Renato·2017·Endocrine

Abstract

To compare the clinical efficacy of tablet and oral liquid L-thyroxine (LT4) formulation in naïve hypothyroid subjects with Helicobacter pylori infection. Forty-seven adult naïve hypothyroid subjects with dyspeptic symptoms were investigated with upper endoscopy and divided into: 28 patients with Helicobacter pylori infection (Group A); 15 patients without gastric alterations (group B); 4 patients with autoimmune gastritis were excluded from the study. Subjects were randomly treated with a same dose of LT4 tablet (TAB) or oral liquid formulation (SOL), for 9 months on group A and 6 months on group B. Helicobacter pylori infection was eradicated after 3 months of LT4 treatment. On group A, after 3 months (before Helicobacter pylori eradication), subjects treated with SOL showed a greater thyroid-stimulating hormone reduction (ΔTSH 3-0 : TAB = -4.1 ± 4.6 mU/L; SOL = -7.7 ± 2.5 mU/L; p = 0.029) and a greater homogeneity in the thyroid-stimulating hormone values (TSH 3mo : TAB = 5.7 ± 4.9 mU/L; SOL = 4.1 ± 2.0 mU/L; p = 0.025), compared to LT4 tablet. At 9 months (after 6 months of Helicobacter pylori eradication) mean thyroid-stimulating hormone values were lower in subjects treated with LT4 tablet (TSH 9mo : TAB = 1.8 ± 1.2 mU/L; SOL = 3.2 ± 1.7 mU/L; p = 0.006). On group B no difference were observed, at each time point, in the mean thyroid-stimulating hormone values and thyroid-stimulating hormone variations between two LT4 formulations. LT4 liquid formulation may produce a b…

Integrity signals

Registry

Crossref · 10.1007/s12020-016-1167-3

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Patients with impaired stomach acid secretion require higher levothyroxine doses.

    “Several studies demonstrate the requirement of higher levothyroxine doses in patients with stomach acid secretion impairment (Centanni et al., 2006; Ribichini et al., 2017).”

    From Thyroid disorders and gastrointestinal dysmotility: an old association (2024) · cites this paper as Ribichini et al., 2017

  • Helicobacter pylori treatment improves TSH levels and lowers the required dose of levothyroxine.

    “In addition, there are studies that show improved levels of TSH upon Helicobacter pylori treatment that lower the required dose of levothyroxine (Centanni et al., 2006; Ribichini et al., 2017).”

    From Thyroid disorders and gastrointestinal dysmotility: an old association (2024) · cites this paper as Ribichini et al., 2017

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 26 · Cited by 35

Authors
Ribichini, D., Fiorini, G., Repaci, A., Castelli, V., Gatta, L., Vaira, D., & Pasquali, R.
Affiliations
  • IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
  • Ospedale Versilia (IT)
Corresponding author
  • Ribichini, Danilo
  • Pasquali, Renato
Venue
Endocrine
Published
2016-11-15
Volume
57
Issue
3
Pages
394-401
ISSN
  • 0969-711X (ISSN-L)
  • 1355-008X
  • 1559-0100
OpenAlex
W2555994508
Cited by
35
References
26
Citations by year
2026: 1 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 7 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 2
FWCI
2.01
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Surgery › Helicobacter pylori-related gastroenterology studies
Keywords
levothyroxine, oral liquid formulation, tablet formulation, hypothyroidism, Helicobacter pylori infection, thyroid-stimulating hormone, dyspepsia, Helicobacter pylori eradication, drug formulation comparison
MeSH terms
Adult, Anti-Ulcer Agents, Anti-Bacterial Agents, Drug Therapy, Combination, Dyspepsia, Female, Gastritis, Humans, Hypothyroidism, Intestinal Absorption, Male, Middle Aged, Pituitary Gland, Anterior, Severity of Illness Index, Tablets, Thyroid Gland, Thyrotropin, Thyroxine, Helicobacter pylori, Helicobacter Infections, Hormone Replacement Therapy, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review